222 related articles for article (PubMed ID: 34836197)
1. Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms.
Sharma M; Arora I; Chen M; Wu H; Crowley MR; Tollefsbol TO; Li Y
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836197
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Activation of
Donovan MG; Selmin OI; Doetschman TC; Romagnolo DF
Nutrients; 2019 Oct; 11(11):. PubMed ID: 31652854
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of multiple tumor-related genes leads to suppression of breast tumorigenesis by dietary genistein.
Li Y; Chen H; Hardy TM; Tollefsbol TO
PLoS One; 2013; 8(1):e54369. PubMed ID: 23342141
[TBL] [Abstract][Full Text] [Related]
6. Maternal soybean genistein on prevention of later-life breast cancer through inherited epigenetic regulations.
Chen M; Li S; Srinivasasainagendra V; Sharma M; Li Z; Tiwari H; Tollefsbol TO; Li Y
Carcinogenesis; 2022 Apr; 43(3):190-202. PubMed ID: 35084457
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition.
Sharma M; Tollefsbol TO
Exp Cell Res; 2022 Jul; 416(1):113160. PubMed ID: 35447103
[TBL] [Abstract][Full Text] [Related]
8. Epi-drugs as triple-negative breast cancer treatment.
Idrissou M; Sanchez A; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Epigenomics; 2020 Apr; 12(8):725-742. PubMed ID: 32396394
[TBL] [Abstract][Full Text] [Related]
9. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
11. Maternal soybean diet on prevention of obesity-related breast cancer through early-life gut microbiome and epigenetic regulation.
Chen M; Li S; Arora I; Yi N; Sharma M; Li Z; Tollefsbol TO; Li Y
J Nutr Biochem; 2022 Dec; 110():109119. PubMed ID: 35933021
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
Kala R; Shah HN; Martin SL; Tollefsbol TO
BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA methylation for treating triple-negative breast cancer.
Yu J; Zayas J; Qin B; Wang L
Pharmacogenomics; 2019 Nov; 20(16):1151-1157. PubMed ID: 31755366
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
17. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
18. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Sole A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E
Mol Cancer Res; 2019 Oct; 17(10):2063-2076. PubMed ID: 31320385
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
20. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
